Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Clinical Study to Evaluate Cannabidiol (CBD) for the Treatment of Autoimmune Hepatitis (AIH)

Next Previous
Search
Trial Profile

A Phase 1/2a Clinical Study to Evaluate Cannabidiol (CBD) for the Treatment of Autoimmune Hepatitis (AIH)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Autoimmune hepatitis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Revive Therapeutics

    • Most Recent Events

    • 25 Feb 2020 New trial record
    • 18 Feb 2020 According to a Revive Therapeutics media release, the company aims to initiate this first-in-kind human clinical trial under a U.S. IND by the end of Q2 or early Q3-2020.
    • 18 Feb 2020 According to a Revive Therapeutics media release, the company is currently in the process of preparing its Investigational New Drug (IND) application for submission to the U.S. Food and Drug Administration (FDA) for Cannabidiol in the treatment of autoimmune hepatitis.The Company plans to submit the IND within ninety days with the objective to proceed with this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top